- Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)Chen, Jinzhang; Zang, Mengya; Pang, Huajin; Li, Chuanjiang; Zhao, Jianbo; Guo, Yabing; Hou, JinlinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 1
- Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)Zang, M.; Li, Q.; Pang, H.; Hu, X.; Li, R.; Yuan, G.; Li, W.; Guo, Y.; Chen, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
- Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).Zhao, Hong; Zhou, Aiping; Tu, Jianfei; Bai, Yuxian; Mao, Xianhai; Song, Tianqiang; Li, Bo; Dai, Wenxiang; Lv, Jing; Wang, Jufeng; Che, Xu; Liu, Lianxin; Zhang, Lianhai; Wu, Wei; Cai, JianqiangAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
16阅读
